- Home
- GUTS vs ONCY Comparison
GUTS vs ONCY Comparison
Compare GUTS & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- ONCY
- Stock Information
- Founded
- GUTS 2010
- ONCY 1998
- Country
- GUTS United States
- ONCY Canada
- Employees
- GUTS N/A
- ONCY N/A
- Industry
- GUTS
- ONCY Pharmaceuticals and Biotechnology
- Sector
- GUTS
- ONCY Health Care
- Exchange
- GUTS NYSE
- ONCY Nasdaq
- Market Cap
- GUTS 58.8M
- ONCY 49.1M
- IPO Year
- GUTS 2024
- ONCY 1999
- Fundamental
- Price
- GUTS $1.58
- ONCY $0.75
- Analyst Decision
- GUTS Buy
- ONCY Strong Buy
- Analyst Count
- GUTS 1
- ONCY 4
- Target Price
- GUTS $10.00
- ONCY $4.33
- AVG Volume (30 Days)
- GUTS 930.5K
- ONCY 1.2M
- Earning Date
- GUTS 08-13-2025
- ONCY 07-31-2025
- Dividend Yield
- GUTS N/A
- ONCY N/A
- EPS Growth
- GUTS N/A
- ONCY N/A
- EPS
- GUTS N/A
- ONCY N/A
- Revenue
- GUTS $60,000.00
- ONCY N/A
- Revenue This Year
- GUTS N/A
- ONCY N/A
- Revenue Next Year
- GUTS N/A
- ONCY N/A
- P/E Ratio
- GUTS N/A
- ONCY N/A
- Revenue Growth
- GUTS N/A
- ONCY N/A
- 52 Week Low
- GUTS $0.87
- ONCY $0.33
- 52 Week High
- GUTS $4.92
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- GUTS 42.52
- ONCY 73.42
- Support Level
- GUTS $1.54
- ONCY $0.56
- Resistance Level
- GUTS $1.82
- ONCY $0.80
- Average True Range (ATR)
- GUTS 0.18
- ONCY 0.09
- MACD
- GUTS -0.07
- ONCY 0.02
- Stochastic Oscillator
- GUTS 5.06
- ONCY 94.74
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.